Crizalk 200mg is used for the therapy of patients with metastatic non-small cell lung cancer.
Crizalk 200mg belongs to type of tyrosine kinase inhibitor. Kinases are enzymes which are included in many functions, involving cell development and reproduction.
Crizalk 200mg inhibits the anaplastic lymphoma kinase (ALK) and the c-MET/hepatocyte growth factor receptor. This action disturbs certain pathways in the cell, which can inhibit the growth of tumor cells.
Crizalk 200mg is made specifically for the treatment of a type of lung cancer in which ALK is overactive due to an abnormality in the ALK gene.
Mechanism of action
More specifically, crizotinib inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteurd'OrigineNantais (RON).
Deformity in the ALK gene result by mutations or translocations may causes expression of oncogenic fusion proteins. Certain patients with NSCLC, they have the EML4-ALK gene.
Crizotinib prohibits ALK tyrosine kinase which basically results in reducedmultiplication of cells which carry the genetic mutation and tumour survivability.
Peak plasma concentration is 4 to 6 hours and bioavailability were 43%.
Volume of distribution is 1772L and plasma protein bounding is 91%
Crizalk metabolised by CYP3A4 and CYP3A5
Crizalk is excreted via feces 63% and 22% via urine and half -life is 42 hours
Select patients for the treatment with Crizalk based on ALK or ROS1 presences in tumor specimens.
The recommended dosage of Crizalk is 250mg orally twice in a day
Administer the Crizalk dose with or without food, until disease progression. Dosage modification :
Crizalk 200 mg taken orally twice daily for First dose reduction
Crizalk250 mg taken orally once daily for Second dose reduction
Permanently discontinue if unable to tolerate Crizalk250 mg taken orally once daily.
• Infection increased
• Eyesight changes
• Bowel changes
• Feeling sick
• Swelling of hands and feet’s
• Decreased appetite
• Liver changes
• Skin rash
Before using Crizalk in some condition, consult with doctor.
Interstitial lung disease/pneumonitis
QT interval prolongation
Severe visual loss